Asep Medical addresses antibiotic failure by developing novel solutions for significant unmet medical needs. ASEP consolidates two existing companies:

Sepset Biosciences develops a diagnostic technology that involves a patient gene expression signature predicting severe sepsis, a significant disease responsible for nearly 20% of all deaths on the planet. SepsetER is a blood-based gene expression assay; results are obtained in ~1hr in the emergency room or intensive care unit.

ABT Innovations’ peptide technology covers a broad range of therapeutic applications, including bacterial biofilm infections, anti-inflammatories, anti-infective immune-modulators and vaccine adjuvants. The company is in the pre-clinical development phase with promising data.